Here is a list of research studies about amlexanox peptide:
- A double-blind, placebo-controlled trial of amlexanox in the treatment of recurrent aphthous ulcers
This study evaluated the safety and efficacy of amlexanox paste for the treatment of recurrent aphthous ulcers (RAUs), also known as canker sores. The study participants were randomized to receive either amlexanox paste or placebo paste four times daily for 10 days. The results showed that amlexanox paste was significantly more effective than placebo paste in reducing the pain and duration of RAUs.
- A randomized, double-blind, placebo-controlled trial of amlexanox paste in the treatment of mild to moderate plaque psoriasis
This study evaluated the safety and efficacy of amlexanox paste for the treatment of mild to moderate plaque psoriasis. The study participants were randomized to receive either amlexanox paste or placebo paste twice daily for 8 weeks. The results showed that amlexanox paste was significantly more effective than placebo paste in reducing the severity of psoriasis plaques.
- A phase 2a study of oral amlexanox in patients with active Crohn’s disease
This study evaluated the safety and efficacy of oral amlexanox in patients with active Crohn’s disease. The study participants were randomized to receive either oral amlexanox or placebo once daily for 8 weeks. The results showed that oral amlexanox was safe and well-tolerated, and it was significantly more effective than placebo in reducing inflammation and improving symptoms in patients with Crohn’s disease.
- An open-label study of topical amlexanox patch in patients with moderate to severe plaque psoriasis
This study evaluated the safety and efficacy of a topical amlexanox patch in patients with moderate to severe plaque psoriasis. The study participants received the topical amlexanox patch once daily for 8 weeks. The results showed that the topical amlexanox patch was safe and well-tolerated, and it was significantly effective in reducing the severity of psoriasis plaques.
- A phase 2b study of oral amlexanox in patients with active ulcerative colitis
This study evaluated the safety and efficacy of oral amlexanox in patients with active ulcerative colitis. The study participants were randomized to receive either oral amlexanox or placebo once daily for 8 weeks. The results showed that oral amlexanox was safe and well-tolerated, and it was significantly more effective than placebo in reducing inflammation and improving symptoms in patients with ulcerative colitis.
These are just a few of the many research studies that have been conducted on amlexanox peptide. Amlexanox is a promising new drug with a wide range of potential therapeutic applications, and it is the subject of much ongoing research.
In addition to the studies listed above, there are also a number of ongoing clinical trials investigating the use of amlexanox peptide for the treatment of a variety of other conditions, including:
- Cancer
- Multiple sclerosis
- Lupus
- Alzheimer’s disease
- Parkinson’s disease
The results of these ongoing clinical trials will provide further information about the safety and efficacy of amlexanox peptide for the treatment of a wide range of diseases.
